$2.600
-0.040 (-1.52%)Zum Schluss
- High
- 2.670
- Open
- 2.640
- VWAP
- 2.61
- Vol
- 264.55K
- Mkt Cap
- 141.72M
- Low
- 2.550
- Amount
- 689.57K
- EV/EBITDA, TTM
- -0.22
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
AI analysis of CervoMed Inc (CRVO)
holdCervoMed Inc is not a good buy right now due to its current price of $2.60, which is significantly below the analyst price target of $7 from Roth Capital. Additionally, the stock has a low RSI of 37.007, indicating it is nearing oversold conditions, but the overall trend remains negative with a year-to-date change of -66.62%. The main risk is the company's ongoing financial losses, with a net income of -6,571,656 USD reported for Q2 2026, which raises concerns about its sustainability and ability to fund future trials.
Bewertungskennzahlen
Event-Zeitleiste
News
8.508-10NewsfilterCervoMed Advances Neflamapimod into Phase 3 Clinical Trials for DLB
8.508-05GlobenewswireCervoMed to Share Progress at Growth Conference
8.508-04GlobenewswireCervoMed Secures Innovation Passport to Accelerate DLB Drug Development
- 8.508-04Newsfilter
CervoMed Secures Innovation Passport to Accelerate DLB Drug Development
- 4.507-14Newsfilter
Neflamapimod Signals DLB Modification at AAIC 2026; 50 mg TID Selected for Phase 3; 80 mg BID Safe in Phase 2
CRVO FAQ — answered by Alphio AI
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
CervoMed Inc is not a good buy right now due to its current price of $2.60, which is significantly below the analyst price target of $7 from Roth Capital. Additionally, the stock has a low RSI of 37.007, indicating it is nearing oversold conditions, but the overall trend remains negative with a year-to-date change of -66.62%. The main risk is the company's ongoing financial losses, with a net income of -6,571,656 USD reported for Q2 2026, which raises concerns about its sustainability and ability to fund future trials.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.